Introduction
Multiple gestation is the most common complication following assisted reproductive technology (ART) treatment. Multiple births following ART are associated with increased risks of adverse perinatal outcomes (Kissin et al., 2005; Wang et al., 2006) and maternal complications (Campbell and Templeton, 2004) and higher cost to the health care system .
Regional registry data show that the reported multiple delivery rate was 22% in Europe in 2004 (Nyboe Andersen et al., 2008) , 31% in USA in 2006 (Centers for Disease Control and Prevention, 2008) and 10% in Australia and New Zealand in 2007 (Wang et al., 2009) . The high rate of multiple delivery following ART is largely explained by the number of embryos transferred (Kissin et al., 2005) .
There is a worldwide tendency to reduce the number of embryos transferred in order to reduce the complications of multiple pregnancy. The shift in clinical practice to single embryo transfer (SET) is the pathway to decrease multiple pregnancies following ART (Criniti et al., 2005) . The Nordic countries and Belgium have successfully implemented a policy of SET, with Sweden having reported that 70% of all embryo transfer cycles being from SET (Nygren, 2007) . In Australia and New Zealand, the regulatory group has advocated SET since 2005 with the aim of minimizing the number of multiple births (Reproductive Technology Accreditation Committee, 2005) . The latest regional report detailed the rise in the proportion of SET in Australia and New Zealand from 32% in 2003 to 64% in 2007. As a result, the multiple delivery rate has declined from 19% in 2003 to 10% in 2007 (Wang et al., 2009) .
The principal reason for double or triple embryo transfer is the perception that the more embryos transferred the better the outcome. This belief by both patients and some clinicians is supported by the literature: the transfer of more than one embryo results in a higher pregnancy and live birth rates (Pandian et al., 2005; Baruffi et al., 2009; Bechoua et al., 2009; Pandian et al., 2009) . A recent observational study showed that the pregnancy rate per transfer was significantly higher in the double embryo transfer (DET) group compared with the elective SET group (49.3 versus 32.1% in the DET and eSET groups, respectively) (Bechoua et al., 2009) . However, none of these studies have reported resulting perinatal outcomes other than pregnancy and live birth rates.
The outcome of ART treatment needs to focus on perinatal outcomes, not pregnancy or live birth. Some studies have used 'take home baby' as the optimum outcome following ART treatment (Botchan et al., 1993; Giorgetti et al., 2006) . We introduced the 'healthy baby' concept (a surviving live born term (≥37 weeks gestational age) single neonate of ≥2500 g birthweight and without congenital anomaly) to indicate the best perinatal outcomes following ART treatment. Our study investigates the association between pregnancy, live delivery and 'healthy baby' and the number of embryos transferred by the number of embryos available, and by the stage of embryo development (cleavage or blastocyst). Our hypothesis is that when 'healthy baby' is used as the measurement of the outcome of pregnancy and hence ART treatment, transfer of a selected single blastocyst is the best treatment strategy.
Methods
We retrospectively analysed data from the Australian and New Zealand Assisted Reproduction Database (ANZARD), and compared outcomes between SET and DET, according to whether the embryos were the only ones available, or whether they were selected from a cohort, as well as according to the stage of embryo development.
Subjects
ANZARD is housed at the Perinatal and Reproductive Epidemiology Research Unit of the University of New South Wales, and consists of data collected annually from all fertility centers in Australia and New Zealand. ANZARD includes information about the oocyte pick-up and number of oocytes collected, in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) fertilization procedures, the number of embryos created, stage of embryo development at transfer, number of embryos transferred, freezing of embryos and donation of gametes or embryos. It also includes information on pregnancy and birth outcomes (birth status, gestational age, birthweight, congenital anomaly and neonatal mortality).
Procedures
The study data set was extracted from ANZARD for women undergoing their first stimulated fresh cycle using follicle stimulating hormone. Data were limited to women aged 18 years or older who used their own oocytes (autologous cycles) between 1 January 2004 and 31 December 2007 (Fig. 1) . Mixed cleavage-blastocyte stage embryo transfer cycles were excluded. A total of 34 035 women who had single or DET at their first fresh autologous cycles were included in the denominator to measure the pregnancy and perinatal outcomes. 
Study factors
The number of embryos available for transfer is defined as: (for transfer of cleavage embryos) number of cleavage embryos transferred + number cleavage embryos frozen; and (for transfer of blastocysts) number of blastocysts transferred + number blastocysts frozen. Embryo transfer cycles were categorized into four groups based on number of embryos available: (i) selective single embryo transfer (SSET): at least two embryos available and only one embryo transferred; (ii) unselective single embryo transfer (USSET), only one embryo available and one embryo transferred; (iii) selective double embryo transfer (SDET), at least three embryos available and two embryos transferred; and (iv) unselective double embryo transfer (USDET), only two embryos available and two transferred.
The woman's age was calculated in completed years at the time of treatment and classified into 5-year groups: ≤24 years, 25 -29 years, 30 -34 years, 35 -39 years and .40 years. The cause of infertility was classified as male factor infertility (a male factor problem was diagnosed and no female factor problem), female factor infertility (tubal disease, endometriosis or other female factor problem were diagnosed and no male factor problem), combined male-female factor infertility (both male and female factor problems were diagnosed), unexplained infertility (neither male nor female factor problem was diagnosed) and not stated. Previous pregnancy of greater than or equal to 20 weeks or more gestation was grouped as yes, no and not stated. Type of fertilization was classified either IVF or ICSI. Stage of embryo development was grouped by cleavage embryos (that is Day 2 or 3 after insemination/ICSI) or blastocysts (Day 5 or 6). The number of embryos available for transfer was grouped as 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 or more embryos and further grouped as 1, 2, 3, 4, 5, 6 or more embryos.
Gestational age was defined as the number of completed weeks of gestation and calculated by the formula: (pregnancy end date 2 embryo transfer date) + 16 days for cleavage embryo transfer and (pregnancy end date 2 embryo transfer date) + 19 days for blastocyst transfer.
Main outcome measures
A clinical pregnancy was defined as one of the following criteria: evidence by ultrasound of intrauterine sac(s) and/or fetal heart(s); examination of products of conception revealing chronic villi; an ectopic pregnancy that had been diagnosed laparoscopically or by ultrasound. A live delivery was defined as a birth event in which one or more babies were live born of greater than or equal to 20 weeks gestation or of 400 g or more birthweight.
An indicator, the 'healthy baby', was developed to demonstrate the best perinatal outcome. The 'healthy baby' was defined as live born term (≥37 weeks gestational age) singleton of ≥2500 g birthweight and surviving for at least 28 days and without a notified/reported congenital anomaly.
Statistical analysis
Patient demographics (woman's age, cause of infertility and previous pregnancy of greater than or equal to 20 weeks or more gestation) were compared by SSET, USSET, SDET and USDET. Rates of clinical pregnancy, live delivery and 'healthy baby' per transfer cycle were measured and compared by the four groups of embryo transfer cycle. Data were further stratified by woman's age group (,35 year, 35 -39 years and ≥40 years) and stage of embryo development (cleavage and blastocyst) for comparison.
Chi-square test was used to measure the association between the outcomes and treatment factors. Univariate Cox regression was used to investigate the chance of live delivery and 'healthy baby' following SSET, USSET, SDET and USDET of cleavage embryos and/or blastocysts. Multivariate Cox regression was used to overcome the influence by potential demographics and treatment confounders. Further Cox regression models separated for cleavage embryos or blastocysts were conducted to estimate the likelihood of live delivery and 'healthy baby' by number of embryos available for transfer for SSET. Analyses were conducted separately for women aged ,35 years, 35-39 years and ≥40 years. Rates ratio (RR) and adjusted rate ratio (ARR) (adjusted for clinics, cause of infertility, previous pregnancy of 20 weeks or more gestation and type of fertilization) and 95% confidence intervals (95% CI) were calculated. Data were analysed with SPSS software (version 17.0; SPSS Inc., Chicago, IL, USA).
Ethics
Ethics approval for this study was granted by the Human Research Ethics Committee of the University of New South Wales, Australia.
Results
Table I details the demographic characteristics by number of embryos transferred. Less than 5% of SSET was in women aged 40 years or older compared with 20.9% of USSET, 16.3% of SDET and 30.5% of USDET. Male factor only infertility was slightly higher in SSET than in other groups of embryo transfer cycles. SDET had marginally higher proportion of women who never had pregnancy of 20 weeks or more gestation (Table I) .
The overall pregnancy rate per transfer cycle was significantly higher for transfer of blastocysts (42.3%) compared with transfer of cleavage embryos (32.4%) (Chi-square test, df ¼ 1, P , 0.01). Transfer of blastocysts had a significantly higher rate of live delivery per transfer cycle (34.6%) than did transfer of cleavage embryos (26.0%) (Chi-square test, df ¼ 1, P , 0.01). Similarly, the 'healthy baby' rate per transfer cycle was significantly higher for transfer of blastocysts (27.4%) than for transfer of cleavage embryos (18.0%) (Chi-square test, df ¼ 1, P , 0.01).
Of cycles where cleavage embryos were transferred, SDET had a significantly higher rate of clinical pregnancy per transfer cycle than SSET regardless of woman's age (Chi-square test, df ¼ 1, P , 0.01 for cycles in women aged ,35 years, P , 0.01 for women aged 35-39 years and P ¼ 0.01 for women aged 40 years or older). Similarly, SDET had significantly higher rate of live delivery per transfer cycle than SSET (Chi-square test, df ¼ 1, P , 0.01 for cycles in women aged ,35 years, P , 0.01 for women aged 35-39 years and P ¼ 0.01 for women aged 40 years or older). However, SSET had significantly higher rate of 'healthy baby' per transfer cycle than SDET in women aged younger than 40 years (Chi-square test, df ¼ 1, P , 0.01 for cycles in women aged ,35 years and P ¼ 0.02 for women aged 35-39 years). There was no significant difference in 'healthy baby' rate per transfer cycle between SDET and SSET in women aged 40 years or older (Chi-square test, df ¼ 1, P ¼ 0.32) (Table II) .
Of cycles where blastocysts were transferred, SDET had a higher rate of clinical pregnancy per transfer cycle in women aged 40 years or older (Chi-square test, df ¼ 1, P ¼ 0.01). There was no significant difference in clinical pregnancy rate per transfer cycle between SDET and SSET for women aged younger than 40 years (Chi-square test, (Table II) .
Transfer of single blastocysts in women aged younger than 35 years achieved the highest rates of live delivery and 'healthy baby' per transfer cycle (46.2 and 38.0%) ( Table II) . Table III compares the live delivery and 'healthy baby' rates per transfer cycle following SSET of a blastocyst against USSET of a blastocyst, SDET of blastocysts, USDET of blastocysts, SSET of a cleavage embryo, USSET of a cleavage embryo, SDET of cleavage embryos and USDET of cleavage embryos. In woman aged younger ,35 years and 35 -39 years, SSET of a blastocyst had a significantly higher rate of 'healthy baby' per transfer cycle than all other groups of embryo transfer cycles. In woman aged 40 years or older, SSET of a blastocyst had a significantly higher rate of 'healthy baby' per transfer cycle than USSET and USDET of blastocysts, and all groups of cleavage embryo transfer cycles. There was no significant difference in 'healthy baby' rate per transfer cycle between SSET and SDET of blastocysts in woman aged 40 years or older (Table III) . SSET, one fresh embryo transferred and at least one embryo frozen; USSET, one fresh embryo transferred and no embryo frozen; SDET, two fresh embryos transferred and at least one embryo frozen; USDET, two fresh embryos transferred and no embryo frozen. BL is for blastocyst(s) and CL is for cleavage embryo(s). a Term live born singleton of ≥2500 g birthweight and survived for at least 28 days and without congenital anomaly. b ARR was adjusted for clinics, cause infertility, previous pregnancy of 20 weeks or more gestation and type of fertilization.
A non-overlapped 95% CI indicates the significantly higher rates of live delivery and 'healthy baby' per transfer cycle when compared within cleavage embryos or blastocysts as well as across cleavage embryos and blastocysts (Table IV) . Table V shows the adjusted rate ratio (ARR) of live delivery and 'healthy baby' per transfer cycle following SSET cycles. For cycles in woman aged younger than 35 years, when five or less cleavage embryos were available, SSET from two, three, four or five cleavage embryos did not vary the rates of live delivery and 'healthy baby' per transfer cycle. However, the live delivery rate and 'healthy baby' rate per transfer cycle following SSET where six or more cleavage embryos were available was 26 and 28% higher than SSET where only two cleavage embryos were available. For SSET of a cleavage embryo in women aged 35 -39 years, there was no significant difference in live delivery and 'healthy baby' per transfer cycle by number of cleavage embryos available (Table V) .
For SSET of a blastocyst in women aged younger than 35 years, there was no significant difference in live delivery and 'healthy baby' per transfer cycle according to number of blastocysts available. In woman aged 35-39 years, the rates of live delivery and 'healthy baby' per transfer cycle did vary by number of embryos available (Table V) .
Of SSET cycles in women aged ,35 years, SSET of a cleavage embryo where two, three, four or five cleavage embryos were available had significantly lower rates of live delivery and 'healthy baby' per transfer cycle compared with SSET of a blastocyst where only two blastocysts were available. There was no significant difference in live delivery and 'healthy baby' rates per transfer cycle between SSET of a cleavage embryo where six or more cleavage embryos were available and SSET of blastocyst where only two blastocysts were available. Of SSET cycles in women aged 35-39 years, there was no significant difference in live delivery and 'healthy baby' rates per transfer cycles between SSET of a blastocyst where only two blastocysts were available and SSET of cleavage embryo regardless number of cleavage embryos available (Table VI) Outcomes of selective single blastocyst transfer
Discussion
This large retrospective population-based study suggests that the optimal strategy to achieve a healthy term singleton is the transfer of a selected single blastocyst. This treatment strategy resulted in the highest rate of births of term live born singletons of normal birthweight and without congenital anomaly. This study also suggests that in clinical practice when two or more embryos are available for transfer, DET would not increase the 'healthy baby' rate per transfer cycle. It also confirms that blastocyst transfer results in significantly higher rates of pregnancy than that of cleavage stage embryos. For SSET of a cleavage embryo in women aged younger than 35 years, there was no significant difference in live delivery and 'healthy baby' rates per transfer cycle among cycles where two, three, four or five cleavage embryos were available. In SSET of a blastocyst, the rates of live delivery and 'healthy baby' per transfer cycle also did not vary by the number of blastocysts available. This finding suggested that regardless of the number of embryos available, SSET should be the preferred practice.
The strength of this cohort study includes the national coverage and the timeliness of the data with inclusion of embryo transfer cycles performed in Australia from 2004 to 2007. This gives the study significant power and allows generalizability of results that would not be possible from clinic-based studies. One limitation of this study is that we are unable to measure treatment outcomes from an initiated cycle due to the structure of ANZARD. The measurement of the outcomes in this study was per transfer cycle. Another limitation of this study is the potential variability in reporting of perinatal outcomes. The information on pregnancy and birth outcomes was not stated for 0.8% of clinical pregnancies of the study cohort. Birthweight, gestation and plurality at birth are reliably defined from the various data sources including hospital records, and self reporting by patients and their obstetricians. However, the information on congenital anomalies and neonatal mortality within ANZARD was likely to be incomplete and this may have led to a marginal overestimate of the healthy baby. It is likely that this bias would be consistent across all treatment strategies. A comparative study of a regional birth defect register with practitioner reporting in Australia found congenital anomalies were underreported by the assisted conception database (Hansen et al., 2007) .
In agreement with the latest literature (Veleva et al., 2006; Bechoua et al., 2009; Gelbaya et al., 2009) , our study found that the clinical pregnancy and live delivery rates per cleavage embryo transfer cycle were significantly higher for SDET than SSET regardless of woman's age. However, when we analyzed blastocyst transfers, we did not find this same association. Among women aged less than 40 years, there was no significant difference in the clinical pregnancy and live delivery rates per blastocyst transfer cycle between SDET and SSET. When the perinatal outcomes were used to measure the success per embryo transfer cycle, our study found that the 'healthy baby' rate per transfer cycle was significantly higher for SSET than SDET among women aged younger than 40 years and no worse for women aged 40 years and older regardless of the stage of embryo development.
It has been suggested that the outcome of ART treatment needs to focus on 'Birth Emphasizing a Successful Singleton at Term' (Healy, 2004) . We agree that a 'healthy baby' should always be the optimum outcome of ART treatment. Treatment should be focused on eliminating poorer perinatal outcomes (Kissin et al., 2005; Wang et al., 2006) , minimizing risk to mothers (Campbell and Templeton, 2004) and limiting the potential burden on the health care system due to multiple births. We advocate extending the definition of a 'healthy baby' to a live born term singleton of normal birthweight without a congenital anomaly who survives the neonatal period.
The classification of selective/unselective embryo transfer in our study was based on quantity not quality of available embryos at the time of embryo transfer. The quantity included the sum of the number of embryo transferred and the number of embryo frozen. ANZARD does not have information on the quality of each embryo. The lower rates of live delivery and 'healthy baby' per transfer cycle following unselective embryo transfer compared with selective embryo transfer are possibly related to the quality of transferred embryos especially for cleavage embryos (Bergh, 2005) . Since there was only one cleavage embryo available for transfer in USSET and two available in USDET, poorer quality embryo(s) may have been transferred (Kearns et al., 2005; Flisser and Licciardi, 2006) . Similarly for blastocysts, when limited cleavage embryos are available, extended blastocyst culture would result in either no transfer or possibly transfer of a poorer quality embryo (Barrenetxea et al., 2005) .
Consistent with other studies, our study found that the clinical pregnancy and live delivery rates per transfer cycle were significantly higher after transfer of blastocysts than after transfer of cleavage embryos (Butterworth, 2001; Papanikolaou et al., 2008) . Transfer of a selected single cleavage embryo was less likely to result in a live delivery and a 'healthy baby' compared with transfer of a selected single blastocyst. The likely explanation of the difference is the natural selection through 2 -3 days of extended culture which allows the reduction in abnormal embryos. Hence the best embryos are proposed to survive through the blastocyst culture process (Butterworth, 2001) .
However, this difference in outcomes between fresh blastocysts and cleavage embryos is reduced when the denominator used is initiated cycle since there is reduced embryo utilization rate of blastocysts compared with cleavage embryos (Papanikolaou et al., 2008) . Since our study was a retrospective analysis of actual transfers in terms of cleavage embryo or blastocyst transfers, we are unable to measure the pregnancy and birth outcomes by initiated cycle. A recent Australian study found that in fresh cycles where no embryo was frozen, 73.1% of fertilized oocytes reached transfer of cleavage embryos compared with 38.5% of fertilized oocytes reaching transfer of blastocysts (Wang, 2008) .
If we make an assumption that approximately half (38.5% of 73.1%) of the cleavage embryos develop to blastocysts, then compare the outcomes SSET where two cleavage embryos were available to USSET of blastocyst, our study found that there was no significant difference in the live delivery rate nor the 'healthy baby' rate per transfer cycle. While, based on the same assumption, when comparing SSET of cleavage embryo where four or five cleavage embryos were available with SSET of blastocyst where two blastocysts were available, the live delivery and 'healthy baby' rates per transfer cycle in women aged ,35 years were significantly lower for the former than the latter.
Since 2005, clinics in Australia have recommended SET for the first ART cycle in women aged younger than 35 years (Reproductive Technology Accreditation Committee, 2005) . This study found that about two-thirds of SSET cycles were in women aged younger than 35 years. Of this age group, 68.4% of cycles had four or more cleavage embryos available and 56.8% cycles had four or more blastocysts available. These findings support the 2007 review which found that embryo transfer cancellation was similar between blastocysts transfer cycles and cleavage embryo transfer cycles for good prognosis patients (Blake et al., 2007) . Even based on the above assumption that half of the cleavage embryos develop to blastocysts, our study suggests that if patients aged less than 35 years had four or more cleavage Outcomes of selective single blastocyst transfer embryos in their first autologous ART cycle, further blastocyst culture would ensure that all patients would have had a SSET of a blastocyst, nearly half of them would have had a live delivery and about 40% would have had a 'healthy baby'.
Our study advocates that the optimum outcome of ART treatment should focus on a 'healthy baby' not pregnancy and live birth. Our findings confirm that an optimal practice of fresh ART treatment is selective single blastocyst transfer. This would result in higher rates of live delivery and more 'healthy babies', especially for patients aged younger than 35 years in their first ART cycle who have had four or more embryos available at Day 2/3. Evaluation of embryos at the cleavage stage and consultation with the patient with respect to the advantage of extended culture to selective single blastocyst transfer will result in better perinatal outcomes following ART treatment.
